Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

A scoring system for predicting malignancy in intraductal papillary mucinous neoplasms of the pancreas: a multicenter EUROPEAN validation

Manuel-Vázquez, A. ; Andersson, B. LU orcid and Ramia, J.M. (2022) In Langenbeck's Archives of Surgery 407(8). p.3447-3455
Abstract
Purpose: A preoperative estimate of the risk of malignancy for intraductal papillary mucinous neoplasms (IPMN) is important. The present study carries out an external validation of the Shin score in a European multicenter cohort. Methods: An observational multicenter European study from 2010 to 2015. All consecutive patients undergoing surgery for IPMN at 35 hospitals with histological-confirmed IPMN were included. Results: A total of 567 patients were included. The score was significantly associated with the presence of malignancy (p < 0.001). In all, 64% of the patients with benign IPMN had a Shin score < 3 and 57% of those with a diagnosis of malignancy had a score ≥ 3. The relative risk (RR) with a Shin score of 3 was 1.37 (95%... (More)
Purpose: A preoperative estimate of the risk of malignancy for intraductal papillary mucinous neoplasms (IPMN) is important. The present study carries out an external validation of the Shin score in a European multicenter cohort. Methods: An observational multicenter European study from 2010 to 2015. All consecutive patients undergoing surgery for IPMN at 35 hospitals with histological-confirmed IPMN were included. Results: A total of 567 patients were included. The score was significantly associated with the presence of malignancy (p < 0.001). In all, 64% of the patients with benign IPMN had a Shin score < 3 and 57% of those with a diagnosis of malignancy had a score ≥ 3. The relative risk (RR) with a Shin score of 3 was 1.37 (95% CI: 1.07–1.77), with a sensitivity of 57.1% and specificity of 64.4%. Conclusion: Patients with a Shin score ≤ 1 should undergo surveillance, while patients with a score ≥ 4 should undergo surgery. Treatment of patients with Shin scores of 2 or 3 should be individualized because these scores cannot accurately predict malignancy of IPMNs. This score should not be the only criterion and should be applied in accordance with agreed clinical guidelines. © 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. (Less)
Please use this url to cite or link to this publication:
author
; and
author collaboration
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Intraductal papillary mucinous neoplasm, Malignancy, Pancreatic neoplasm, Preoperative diagnosis, Score
in
Langenbeck's Archives of Surgery
volume
407
issue
8
pages
9 pages
publisher
Springer
external identifiers
  • scopus:85139612845
  • pmid:36198881
ISSN
1435-2443
DOI
10.1007/s00423-022-02687-2
language
English
LU publication?
yes
id
e6a321e0-9244-4da0-b4f2-938e8b563c8d
date added to LUP
2022-12-20 13:31:48
date last changed
2025-04-04 14:34:11
@article{e6a321e0-9244-4da0-b4f2-938e8b563c8d,
  abstract     = {{Purpose: A preoperative estimate of the risk of malignancy for intraductal papillary mucinous neoplasms (IPMN) is important. The present study carries out an external validation of the Shin score in a European multicenter cohort. Methods: An observational multicenter European study from 2010 to 2015. All consecutive patients undergoing surgery for IPMN at 35 hospitals with histological-confirmed IPMN were included. Results: A total of 567 patients were included. The score was significantly associated with the presence of malignancy (p &lt; 0.001). In all, 64% of the patients with benign IPMN had a Shin score &lt; 3 and 57% of those with a diagnosis of malignancy had a score ≥ 3. The relative risk (RR) with a Shin score of 3 was 1.37 (95% CI: 1.07–1.77), with a sensitivity of 57.1% and specificity of 64.4%. Conclusion: Patients with a Shin score ≤ 1 should undergo surveillance, while patients with a score ≥ 4 should undergo surgery. Treatment of patients with Shin scores of 2 or 3 should be individualized because these scores cannot accurately predict malignancy of IPMNs. This score should not be the only criterion and should be applied in accordance with agreed clinical guidelines. © 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.}},
  author       = {{Manuel-Vázquez, A. and Andersson, B. and Ramia, J.M.}},
  issn         = {{1435-2443}},
  keywords     = {{Intraductal papillary mucinous neoplasm; Malignancy; Pancreatic neoplasm; Preoperative diagnosis; Score}},
  language     = {{eng}},
  number       = {{8}},
  pages        = {{3447--3455}},
  publisher    = {{Springer}},
  series       = {{Langenbeck's Archives of Surgery}},
  title        = {{A scoring system for predicting malignancy in intraductal papillary mucinous neoplasms of the pancreas: a multicenter EUROPEAN validation}},
  url          = {{http://dx.doi.org/10.1007/s00423-022-02687-2}},
  doi          = {{10.1007/s00423-022-02687-2}},
  volume       = {{407}},
  year         = {{2022}},
}